Intellia Therapeutics, Inc. [NASDAQ:NTLA]: Analyst Rating and Earnings

Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Regarding Intellia Therapeutics, Inc. [NTLA], the latest average analyst recommendation we can see is from the quarter closing in December. On average, stock market experts give NTLA an Outperform rating. The average 12-month price forecast for this stock is $33.75, with the high estimate being $57.50, the low estimate being $19.00 and the median estimate amounting to $30.00. This is compared to its latest closing price of $14.24.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Intellia Therapeutics, Inc. [NTLA] is sitting at 2.25. This is compared to 1 month ago, when its average rating was 1.88.

For the quarter ending in Sep-18 Intellia Therapeutics, Inc. [NTLA] generated $0.01 billion in sales. That’s 33.08% lower than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Pay attention for this company’s financial results, of which the next release is scheduled to happen on Wed 13 Mar (In 59 Days).

Fundamental Analysis of Intellia Therapeutics, Inc. [NTLA]

Now let’s turn to look at profitability: with a current Operating Margin for Intellia Therapeutics, Inc. [NTLA] sitting at -266.32. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -27.25, and its Return on Invested Capital has reached -23.10%. Its Return on Equity is -26.46, and its Return on Assets is -20.01. These metrics suggest that this Intellia Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is -4.04. The Enterprise Value to Sales for this firm is now 9.20. Intellia Therapeutics, Inc. [NTLA] has a Price to Book Ratio of 2.71.

Shifting the focus to workforce efficiency, Intellia Therapeutics, Inc. [NTLA] earns $133,933 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.09 and its Total Asset Turnover is 0.08. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 11.32 and its Current Ratio is 11.32. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Intellia Therapeutics, Inc. [NTLA] has 42.36M shares outstanding, amounting to a total market cap of $596.85M. Its stock price has been found in the range of 11.03 to 35.99. At its current price, it has moved by -60.85% from its 52-week high, and it has moved 27.73% from its 52-week low.

This stock’s Beta value is currently , which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 45.72. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Intellia Therapeutics, Inc. [NTLA] a Reliable Buy?

Intellia Therapeutics, Inc. [NTLA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.